Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 77

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 77
---
, Euroclear and Clearstream have no knowledge of the actual beneficial owners of interests in a global security. DTC’s records reflect only the identity of the DTC participants to whose accounts those global securities are credited, which may or may not be the beneficial owners of interests in a global security. Similarly, the records of Euroclear and Clearstream reflect only the identity of the Euroclear or Clearstream participants to whose accounts global securities are credited, which also may or may not be the beneficial owners of interests in a global security. DTC, Euroclear and Clearstream participants and indirect participants will remain responsible for keeping account of their holdings on behalf of their customers.

None of the issuer, the Guarantor (if applicable), or any underwriters of the senior debt securities, nor any of its or their respective agents will have any responsibility for the performance by any depositary or their respective participants of their respective obligations under the rules and procedures governing their operations.

#### Other Clearing Systems
The issuer may choose any other clearing system for a particular series of senior debt securities. The clearance and settlement procedures for the clearing system it chooses will be described in the applicable prospectus supplement or free writing prospectus.

<div align='center'>-24-</div>

### TAXATION
The material Japanese tax and U.S. federal income tax consequences relating to the purchase and ownership of the senior debt securities offered by this prospectus will be set forth in the applicable prospectus supplement.

<div align='center'>-25-</div>

### PLAN OF DISTRIBUTION

#### General
We may sell senior debt securities:

• to or through underwriting syndicates represented by managing underwriters;

• through one or more underwriters without a syndicate for them to offer and sell to the public;

• through the issuance of subscription rights to our existing securityholders;

• through dealers or agents;

• to investors directly in negotiated sales or in competitively bid transactions; and

• through a combination of any of the foregoing methods of sale.

Any underwriter or agent involved in the offer and sale of any series of the senior debt securities will be named in the prospectus supplement.

The prospectus supplement for each series of senior debt securities will describe:

• the terms of the offering of these senior debt securities, including the name or names of any agent or agents or the name or names of any underwriters;

• the public offering or purchase price;

• any discounts and commissions to be allowed or paid to any agents or underwriters and all other items constituting underwriting compensation;

• any